Galvani Bioelectronics, a clinical-stage therapeutics company formed through a strategic partnership between GSK and Verily Life Sciences to develop targeted neuromodulation therapies, announced it is recruiting the randomized, controlled stage of a clinical feasibility study for patients with Rheumatoid Arthritis (RA). This progression has been approved by the US Food and Drug Administration (FDA) following review of safety and initial effectiveness from a first group of patients.
Patients with active RA who have had inadequate response to multiple prior targeted therapies can enroll in the study in multiple areas in the US including New York City (NY), Dallas-Fort Worth (TX), Austin (TX), San Antonio (TX), Los Angeles (CA), Portland (OR), Altoona (PA), and Hagerstown (MD) as well as in Amsterdam and Eindhoven in the Netherlands.
The investigational treatment is the first in the clinic to directly stimulate the splenic nerve and Galvani’s therapeutic platform is the first to electrically stimulate nerves specific to individual visceral organs central in disease.
Also Read: Sapio Sciences Launches Partner Program to Accelerate Research and Diagnostics
To lead clinical development on the back of this positive initial clinical readout, Dr. Raolat Abdulai will join the company as Chief Medical Officer in August. Dr. Abdulai joins from Sanofi where she was global clinical lead for the development of Dupixent (dupilumab) across multiple indications, including a recent first approval for a biologic in COPD in the EU.
“I’m delighted to welcome Raolat. She brings great leadership, deep expertise, and critical experience in developing transformational immunology therapies. This comes at a pivotal time for the clinical development of the full potential of our lead therapy and wider therapy platform,” said Dr. Kris Famm, President and CEO of Galvani.
“I am thrilled to be joining Galvani at this critical point. The company’s platform has the potential to revolutionize the way we treat disease. I look forward to working with Kris and the Galvani team to bring this technology to patients,” said Dr. Abdulai.
SOURCE: Businesswire